173 related articles for article (PubMed ID: 15911321)
1. From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors.
Bhhatarai B; Garg R
Bioorg Med Chem; 2005 Jun; 13(12):4078-84. PubMed ID: 15911321
[TBL] [Abstract][Full Text] [Related]
2. Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.
Garg R; Patel D
Bioorg Med Chem Lett; 2005 Aug; 15(16):3767-70. PubMed ID: 15993582
[TBL] [Abstract][Full Text] [Related]
3. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
Garg R; Bhhatarai B
Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
Debnath AK
J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
[TBL] [Abstract][Full Text] [Related]
5. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
Santos-Filho OA; Hopfinger AJ
J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
7. Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease.
Senese CL; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(4):1297-307. PubMed ID: 12870923
[TBL] [Abstract][Full Text] [Related]
8. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
Lu D; Sham YY; Vince R
Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
[TBL] [Abstract][Full Text] [Related]
9. Prediction of HIV-1 protease inhibitory activity of 4-hydroxy-5,6-dihydropyran-2-ones: QSAR study.
Ravichandran V; Mourya VK; Agrawal RK
J Enzyme Inhib Med Chem; 2011 Apr; 26(2):288-94. PubMed ID: 20735159
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 protease inhibitors: a comparative QSAR analysis.
Kurup A; Mekapati SB; Garg R; Hansch C
Curr Med Chem; 2003 Sep; 10(17):1679-88. PubMed ID: 12871116
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis.
Nunthanavanit P; Anthony NG; Johnston BF; Mackay SP; Ungwitayatorn J
Arch Pharm (Weinheim); 2008 Jun; 341(6):357-64. PubMed ID: 18442018
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
13. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
14. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
Sperka T; Pitlik J; Bagossi P; Tözsér J
Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of triazolamers as active site inhibitors of HIV-1 protease.
Jochim AL; Miller SE; Angelo NG; Arora PS
Bioorg Med Chem Lett; 2009 Nov; 19(21):6023-6. PubMed ID: 19800230
[TBL] [Abstract][Full Text] [Related]
16. Quantitative structure-activity relationship studies on 1-aryl-tetrahydroisoquinoline analogs as active anti-HIV agents.
Chen KX; Xie HY; Li ZG; Gao JR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5381-6. PubMed ID: 18835162
[TBL] [Abstract][Full Text] [Related]
17. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
[TBL] [Abstract][Full Text] [Related]
18. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.
Tait BD; Hagen S; Domagala J; Ellsworth EL; Gajda C; Hamilton HW; Prasad JV; Ferguson D; Graham N; Hupe D; Nouhan C; Tummino PJ; Humblet C; Lunney EA; Pavlovsky A; Rubin J; Gracheck SJ; Baldwin ET; Bhat TN; Erickson JW; Gulnik SV; Liu B
J Med Chem; 1997 Nov; 40(23):3781-92. PubMed ID: 9371244
[TBL] [Abstract][Full Text] [Related]
19. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
Wannberg J; Sabnis YA; Vrang L; Samuelsson B; Karlén A; Hallberg A; Larhed M
Bioorg Med Chem; 2006 Aug; 14(15):5303-15. PubMed ID: 16621572
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
